Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population

Molecular Vision

Volumn 19, Issue , 2013, Pages 702-709

  Chang, Woohyok ^a   Noh, Dong Hyoun ^a   Sagong, Min ^a   Kim, In Taek ^b  

^a Yeungnam University College of Medicine   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

AGED; AMRS2 GENE; ARTICLE; CENTRAL MACULAR THICKNESS; CFH GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HTRA1 GENE; HUMAN; KDR GENE; KOREA; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VEGFA GENE; VISUAL ACUITY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ASIAN CONTINENTAL ANCESTRY GROUP; DEMOGRAPHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; PHARMACOGENETICS; REPUBLIC OF KOREA; SMOKING; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84875433957     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004; 137:486-95. [PMID: 15013873].
2. Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007; 85:425-30. [PMID: 17714704].
3. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-31. [PMID: 17021318].
4. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114:1868-75. [PMID: 17628683].
5. Mariani A, Deli A, Ambresin A, Mantel I. Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2011; 249:1635-42. [PMID: 21725716].
6. Seddon JM, Reynolds R, Rosner B. Peripheral retinal drusen and reticular pigment: Association with CFHY402H and CFHrs1410996 genotypes in family and twin studies. Invest Ophthalmol Vis Sci 2009; 50:586-91. [PMID: 18936151].
7. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308:385-9. [PMID: 15761122].
8. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308:421-4. [PMID: 15761121].
9. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308:419-21. [PMID: 15761120].
10. Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet 2005; 77:389-407. [PMID: 16080115].
11. Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Weber BH. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005; 14:3227-36. [PMID: 16174643].
12. Dewan A, Liu M, Hartman S, Zhang SS, Liu DT, Zhao C, Tam PO, Chan WM, Lam DS, Snyder M, Barnstable C, Pang CP, Hoh J. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006; 314:989-92. [PMID: 17053108].
13. Churchill AJ, Carter JG, Lovell HC, Ramsden C, Turner SJ, Yeung A, Escardo J, Atan D. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet 2006; 15:2955-61. [PMID: 16940309].
14. Galan A, Ferlin A, Caretti L, Buson G, Sato G, Frigo AC, Foresta C. Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor. Ophthalmology 2010; 117:1769-74. [PMID: 20471686].
15. Gotoh N, Yamada R, Hiratani H, Renault V, Kuroiwa S, Monet M, Toyoda S, Chida S, Mandai M, Otani A, Yoshimura N, Matsuda F. No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese. Hum Genet 2006; 120:139-43. [PMID: 16710702].
16. Gotoh N, Yamada R, Nakanishi H, Saito M, Iida T, Matsuda F, Yoshimura N. Correlation between CFH Y402H and HTRA1 rs11200638 genotype to typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy phenotype in the Japanese population. Clin Experiment Ophthalmol 2008; 36:437-42. [PMID: 18939352].
17. Gotoh N, Nakanishi H, Hayashi H, Yamada R, Otani A, Tsujikawa A, Yamashiro K, Tamura H, Saito M, Saito K, Iida T, Matsuda F, Yoshimura N. ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Am J Ophthalmol 2009; 147:1037-41. [PMID: 19268887].
18. Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007; 114:2168-73. [PMID: 18054635].
19. Nischler C, Oberkofler H, Ortner C, Paikl D, Riha W, Lang N, Patsch W, Egger SF. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol (Copenh) 2011; 89:e344-9. [PMID: 21232084].
20. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA Jr. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2009; 93:610-3. [PMID: 19091853].
21. Francis PJ. The influence of genetics on response to treatment with ranibizumab (lucentis) for age-related macular degeneration: The lucentis genotype study (an American ophthalmological society thesis). Trans Am Ophthalmol Soc 2011; 109:115-56.
22. McKibbin M, Ali M, Bansal S, Baxter PD, West K, Williams G, Cassidy F, Inglehearn CF. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012; 96:208-12. [PMID: 21558292].
23. Menghini M, Kloeckener-Gruissem B, Fleischhauer J, Kurz-Levin MM, Sutter FK. Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degeneration. PLoS ONE 2012; 7:e42014-[PMID: 22848690].
24. Orlin A, Hadley D, Chang W, Ho AC, Brown G, Kaiser RS, Regillo CD, Godshalk AN, Lier A, Kaderli B, Stambolian D. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 2012; 32:4-9. [PMID: 21878851].
25. Bessho H, Honda S, Kondo N, Negi A. The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Mol Vis 2011; 17:977-82. [PMID: 21541271].
26. Park DH, Kim IT. Polymorphisms in the VEGF-A in polypoidal choroidal vasculopathy in a Korean population. Jpn J Ophthalmol 2012; 56:145-51. [PMID: 22307775].
27. Park DH, Kim IT. Association of ARMS2/HTRA1 variants with polypoidal choroidal vasculopathy phenotype in a Korean population. Jpn J Ophthalmol 2012; 56:60-7. [PMID: 21959923].
28. Nakata I, Yamashiro K, Nakanishi H, Tsujikawa A, Otani A, Yoshimura N. VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration. Jpn J Ophthalmol 2011; 55:435-43. [PMID: 21744122].
29. Lima LH, Schubert C, Ferrara DC, Merriam JE, Imamura Y, Freund KB, Spaide RF, Yannuzzi LA, Allikmets R. Three major loci involved in age-related macular degeneration are also associated with polypoidal choroidal vasculopathy. Ophthalmology 2010; 117:1567-70. [PMID: 20378180].
30. Sayed KM, Naito T, Nagasawa T, Katome T, Mitamura Y. Early visual impacts of optical coherence tomographic parameters in patients with age-related macular degenera¬tion following the first versus repeated ranibizumab injection. Graefes Arch Clin Exp Ophthalmol 2011; 249:1449-58. [PMID: 21494878].
31. Gerding H, Loukopoulos V, Riese J, Hefner L, Timmermann M. Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. Graefes Arch Clin Exp Ophthalmol 2011; 249:653-62. [PMID: 21387180].
32. Kim YM, Kim JH, Koh HJ. Improvement of photoreceptor integrity and associated visual outcome in neovascular age-related macular degeneration. Am J Ophthalmol 2012; 154:164-73. [PMID: 22541932].